GSK’s Boostrix Receives FDA Approval

GlaxoSmithKline has revealed that its booster vaccine, Boostrix has been approved by the US Food and Drug Administration

GlaxoSmithKline has revealed that its booster vaccine, Boostrix has been approved by the US Food and Drug Administration to be used as a single dose booster vaccine to treat tetanus, diphtheria and whooping cough in people over 65 years of age.

Boostrix has already been approved by the FDA for adolescents between 10 to 18 years of age and for adults aged between 19 to 64 years.

Tetanus - Causes Symptoms Diagnosis Treatment FAQs
Tetanus (or Lockjaw) is a serious preventable infection that can affect the muscles and nerves and results from contamination of wound. The vaccine against Tetanus can prevent the infection.

While there are other vaccine to treat individual diseases for the elderly, FDA said that this will be the first vaccine to provide protection against all three diseases among the elderly.

“Pertusis is a highly contagious disease, and outbreaks have occurred among the elderly in nursing homes and hospitals. With this approval, adults 65 and older now have the opportunity to receive a vaccine that prevents pertussis, as well as tetanus and diphtheria”, FDA’s Karen Midthun said.

Source-Medindia

Haryana Declared Neonatal Tetanus-free
Haryana has been declared free of neonatal tetanus by the central government.

Paucity of Tetanus Vaccine
New Zealand: The supply of tetanus vaccine meant for children below seven is fast depleting, which has sent the Ministry of Health in a tizzy to manage replacements.